Professional Summary

Professional Overview

Greg Zante is an experienced finance executive with a proven track record of driving strategic growth and operational excellence. As the Senior Vice President of Finance at Viking Therapeutics, Inc., he oversees the company's financial operations, capital planning, and business development initiatives. With a deep understanding of the biopharmaceutical industry, Zante leverages his expertise to support Viking's mission of developing innovative therapies.

Experience Summary

Current Role

In his current role as Senior Vice President of Finance at Viking Therapeutics, Inc., Zante is responsible for leading the company's financial strategy and management. He oversees all aspects of the finance function, including budgeting, forecasting, treasury, and compliance. Zante has been instrumental in securing strategic funding to advance Viking's clinical pipeline and support its growth initiatives. Under his leadership, the company has maintained a strong financial position, enabling it to invest in key research and development projects.

Career Progression

Zante's extensive finance experience spans nearly three decades, with a focus on the biopharmaceutical and healthcare sectors. Prior to his current role, he served as the Senior Vice President of Finance and Vice President of Finance and Operations at Viking Therapeutics, Inc. Zante has also held senior finance positions at Dance Biopharm, Inc., Sangamo Therapeutics, Inc., and Calyx Therapeutics, Inc., where he played a pivotal role in driving financial strategy, streamlining operations, and supporting business growth.

Academic Background

Zante holds a Bachelor of Science degree in Accounting from the University of California, Los Angeles. He is a Certified Public Accountant (CPA) and has a strong background in financial reporting, analysis, and strategic planning.

Areas of Expertise

• Financial management and strategic planning

• Capital raising and investor relations

• Mergers, acquisitions, and business development

• Financial modeling and forecasting

• Regulatory compliance and risk management

• Leadership and team building

Professional Impact

Throughout his career, Zante has demonstrated a commitment to driving financial and operational excellence. He has successfully navigated complex financial and regulatory environments, enabling the organizations he has served to achieve their strategic objectives. Zante's expertise and leadership have contributed to the growth and success of several biopharmaceutical companies, including Viking Therapeutics, where he has played a crucial role in securing funding and advancing the company's clinical pipeline.

Conclusion

With his extensive finance experience, industry knowledge, and strategic mindset, Greg Zante is a valuable asset to Viking Therapeutics. As the company continues to expand its portfolio and pursue new opportunities, Zante's leadership in the finance function will be instrumental in sustaining the company's financial health and supporting its long-term success.